Business Context and Reporting Period
Company: Inventiva S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: July 2026
Date of Filing: July 9, 2026
Principal Executive Offices: 50 rue de Dijon, 21121 Daix, France
This filing serves to distribute a press release issued by the Registrant on July 9, 2026, which is attached as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to disseminate a press release and does not contain a financial statement or detailed operational data within the provided text.
Material Changes
The filing text does not disclose specific material changes versus prior periods. The content is limited to the notification of the press release issuance.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or details on unusual items. These details are presumably contained within the attached Exhibit 99.1 (Press Release), the text of which is not included in the input.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) to understand the specific announcement made on July 9, 2026.
- Verify the impact of the announcement on the company's clinical pipeline or strategic partnerships, as Inventiva S.A. is a biopharmaceutical company.
- Check subsequent filings for any financial implications resulting from the event described in the press release.